Combined net integrity PBO and LLINs-PLOS1. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

Factors affecting pyrethroid-LLINs integrity. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

Factors associated with mosquito net integrity. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

LLINs knockdown performance over time. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

Factors affecting PBO-LLINs integrity. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

Net bioefficacy data. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

House structure and status. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

LLINs hole positions over time. by Job Oyweri (22041452)

“…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”

Efflux pump inhibitors NMP and PLU inhibit the viability of <i>Mycobacterium abscessus</i> biofilms. by Timilehin Faboro (20175963)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Table 3_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

“…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”

Table 1_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

“…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”

Table 2_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

“…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”

Prognostic indicators and survival rates in vulvar cancer: insights from a retrospective study by Tharinee Rahong (21020147)

“…Multivariate analysis indicated that coexisting lesions such as Paget’s disease and lichen sclerosus, positive lymphovascular space invasion (LVSI), pelvic or para-aortic lymph node involvement, and positive p53 expression were significantly linked to reduced PFS. Additionally, a tumour size greater than 4 cm was associated with decreased OS. …”

Infrared thermal images of typical subjects. by Yongliang Jiang (6200549)

“…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO₂ of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”

The CONSORT flowchart of the study. by Yongliang Jiang (6200549)

“…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO₂ of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”

Location of 4 somatic measurement sites. by Yongliang Jiang (6200549)

“…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO₂ of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”

Minimal data set. by Yongliang Jiang (6200549)

“…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO₂ of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”